A phase I study of bolus high dose interleukin-2 [aldesleukin] with sorafenib (BAY 43-9006) in patients with unresectable or metastatic clear cell renal carcinoma (RCC).

Trial Profile

A phase I study of bolus high dose interleukin-2 [aldesleukin] with sorafenib (BAY 43-9006) in patients with unresectable or metastatic clear cell renal carcinoma (RCC).

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Aldesleukin (Primary) ; Sorafenib (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Apr 2014 Status changed from active, no longer recruiting to completed, according to results published in the Journal of Immunotherapy.
    • 19 Jun 2013 Planned end date changed from 1 Jun 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top